Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s. · BIST:ECILC
Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s — EİS Eczacıbaşı Pharmaceutical and Industrial Investment — Shareholder Meeting (April 2021)
22 slides from Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s's shareholder meeting presentation, Apr 13, 2021
Slide 1: Ordinary General Assembly Meeting 13 April 2021
EİS ECZACIBAŞI PHARMACEUTICAL AND INDUSTRIAL INVESTMENT CO. ORDINARY GENERAL ASSEMBLY MEETING 13 APRIL 2021 1
Slide 2: Table of Contents
TABLE OF CONTENTS General Information Activity Information Consolidated Health Real Estate Development Future Strategies BIST Indicators 2/21
Slide 3: General Information
General Information Shareholding Structure Affiliates and Partnerships Existing Consolidated Structure 3/21
Slide 4: Shareholding Structure
SHAREHOLDING STRUCTURE SHARE AMOUNT SHAREHOLDING NAME OF THE SHAREHOLDER (TL) RATIO (%) ECZACIBAŞI HOLDİNG A.Ş. 346,845,460 50.62 ECZACIBAŞI YATIRIM HOLDİNG ORT. A.Ş. 203,484,584 29.69 PUBLIC SHAREHOLDERS (Out-of-Group Shares) 134,929,955 19.69 TOTAL 685,260,000 100.00 (*) Eczacıbaşı Yatırım Holding
Slide 5: Affiliates and Partnerships
AFFILIATES AND PARTNERSHIPS NOMINAL SHAREHOLDING SHAREHOLDING CAPITAL RATIO AMOUNT (TL) (%) (TL) SUBSIDIARIES EİP Eczacıbaşı İlaç Pazarlama A.Ş. 99.92 56,055,120 56,100,000 Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş. 99.49 2,487,353 2,500,000 Eczacıbaşı İlaç Ticaret A.Ş. 94.70 47,350 50,000 JO
Slide 6: Existing Consolidated Structure
EXISTING CONSOLIDATED STRUCTURE ECILC Health Real Estate Development Other (Partnerships and Activities) • Ecz. İlaç Pazarlama 99.9% • Ecz. Holding 37.3% • Ecz. Gayrimenkul A.Ş. 99.5% • Ecz. İlaç Ticaret 99.8% • Ecz. Dış Ticaret 26.4% • Kanyon Ofis 100% • Ecz.- Monrol 81% • Vitra Karo 25% • Kanyon A
Slide 7: Activity Information
Activity Information Consolidated Health Real Estate Development 7/21
Slide 8: Consolidated Indicators for 2019 - 2020
CONSOLIDATED INDICATORS FOR 2019 - 2020 (TL MILLION) 2019 2020 ∆ (%) Consolidated Total Assets : 4,838 5,970 23.4 Consolidated Total Equity : 4,277 5,282 23.5 8/21
Slide 9: Consolidated Indicators for 2019 - 2020
CONSOLIDATED INDICATORS FOR 2019 - 2020 2019 (TL MILLON) 2020 877 909 1.000 400 322 800 300 600 163 200 400 200 100 0 0 CONSOLIDATED CONSOLIDATED REVENUE PROFIT FOR THE PERIOD 9/21
Slide 10: 2020 Financial Data on Subsidiaries, Affiliates and Joint Ventures
2020 FINANCIAL DATA ON SUBSIDIARIES, AFFILIATES AND JOINT VENTURES Net Income / Direct Operating Loss for the Shareholding Capital Assets Equity Revenue Profit / Loss Period As of 31 December 2020 (*) Ratio (%) (TL) (TL Thousand) (TL Thousand) (TL Thousand) (TL Thousand) (TL Thousand) Subsidiaries E
Slide 11: Consolidated Segment Developments - Health
2020 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - MATERIAL DEVELOPMENTS IN THE SECTOR According to the IMS data, the Turkish Pharmaceutical Market grew by 21% on TL basis and reached TL 46.5 billion in 2020. In view of hospital IMS data, it reached 5.7 TL billion by growing 8% on TL basis. Pur
Slide 12: Consolidated Segment Developments - Health
2020 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - MATERIAL DEVELOPMENTS IN THE SECTOR Due to the effect of Covid-19 pandemic, the number of people presenting to outpatient clinics decreased significantly. In view of the services paid under SSI; - The number of presentations decreased from 573 thou
Slide 13: Consolidated Segment Developments - Health
2020 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı İlaç Pazarlama In the field of vitamin, mineral and supplements sector, which flourished as a result of an increased awareness about ‘Healthy Lifestyle’, we continued to diversify the product portfolio of Dynav
Slide 14: Consolidated Segment Developments - Health
2020 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı İlaç Pazarlama An Asset Acquisition and Transfer Agreement was entered into by and between EİP and Baxter Turkey on 5 February 2021 on termination of the distribution business of hospital products related to Ba
Slide 15: Consolidated Segment Developments - Health
2020 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES Nuclear Medicine Eczacıbaşı - Monrol Consolidated sales grew by 25% in 2020. The focus was on improvement of exports and foreign sales of subsidiaries, and foreign-based income surpassed domestic income for the first ti
Slide 16: Consolidated Segment Developments - Health
2020 CONSOLIDATED SEGMENT DEVELOPMENTS - HEALTH - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı - Monrol Under the undertaking indicated in the Amendment Protocol dated 31 October 2017, a share transfer agreement was entered into by and between Eczacıbaşı Group and Bozlu Group on 27 October 2020 upon the
Slide 17: Consolidated Segment Developments - Real Estate Development
2020 CONSOLIDATED SEGMENT DEVELOPMENTS - REAL ESTATE DEVELOPMENT - KANYON We focused on events and digital projects that bring forward safe shopping outdoors at Kanyon, in which EİS owns 100% of the office block and 50% of the Mall, in order to minimize the effects of the environment resulting fro
Slide 18: Future Strategies
>» Future Strategies e Eczacibasi 18/21
Slide 19: Future Strategies
FUTURE STRATEGIES HEALTH It is aimed to keep pace with developments emerging in the healthcare sector; To expand the portfolio of Rare Diseases, Oncology, Vitamin-Mineral and Supplements, To increase overseas operations in the field of nuclear medicine, To grow in the field of Nuclear Medici
Slide 20: BIST Indicators
> BIST Indicators e Eczacibasi 20/21
Slide 21: ECILC - BIST100 Performance Summary (2020 year)
ECILC - BIST100 PERFORMANCE SUMMARY (2020 year) 21/21
Slide 22: Thank You
> THANK YOU ... —/,
EİS Eczacıbaşı Pharmaceutical and Industrial Investment — Shareholder Meeting (April 2021) on 6ix